TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer
Journal for ImmunoTherapy of Cancer · 2026-04 · 14 (4) · e012265
DOI: 10.1136/jitc-2025-012265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.04.2026. Verfasst von Bogang Wu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA lellisen@mgh.harvard.edu wu.bogang@mayo.edu. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Cell Adhesion Molecules, Immune Checkpoint Inhibitors, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Congressionally Directed Medical Research Programs, National Cancer Institute.
Abstract (Originalsprache)
Background
Immune exclusion inhibits antitumor immunity and response to immunotherapy, but its mechanisms remain poorly defined. In triple-negative breast cancer (TNBC), an aggressive and generally immune-rich subtype, an immune-cold microenvironment predicts poor prognosis due to a limited response to chemotherapy and immune checkpoint inhibitors. This study aimed to identify mechanisms regulating immune infiltration in TNBC.
Methods
We performed spatial transcriptomic analysis comparing immune-enriched versus immune-cold treatment-naïve TNBCs. Functional analyses, including loss-of-function and reconstitution experiments, were conducted to investigate the role of trophoblast cell-surface antigen 2 (TROP2), a key target of anticancer antibody drug conjugates (ADCs), in promoting TNBC progression. A humanized TROP2 syngeneic TNBC model was used to assess the effects of TROP2-targeting in combination with anti-programmed cell death protein 1 (PD-1) therapy. Additionally, data from patients treated with immune checkpoint blockade were used to test hypotheses from the preclinical findings.
Results
We reveal that TROP2 controls barrier-mediated immune exclusion in TNBC through claudin 7 association and tight junction regulation. TROP2 expression is inversely correlated with T-cell infiltration and predicts poor outcomes in TNBC. We demonstrate that TROP2 is sufficient to drive tumor progression in vivo in a CD8 T cell-dependent manner, while its loss deregulates expression and localization of multiple tight junction proteins, enabling T-cell infiltration. We show that TROP2 targeting via hRS7, the antibody component of the ADC sacituzumab govitecan, enhances the anti-PD-1 response and improves T-cell accessibility and effector function. Correspondingly, TROP2 expression is highly associated with lack of response to anti-PD-1 therapy in human breast cancer.
Conclusions
This study defines a new mechanism of barrier-mediated immune exclusion in cancer controlled by TROP2-dependent tight junctions. This mechanism drives tumor progression but can be targeted via TROP2-directed therapy to activate antitumor immunity and enhance immunotherapy response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA lellisen@mgh.harvard.edu wu.bogang@mayo.edu.
- Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
- Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Ludwig Center at Harvard, Boston, Massachusetts, USA.
Förderung
- NCI NIH HHS
- Congressionally Directed Medical Research Programs
- National Cancer Institute
Zitieren
APA
Wu, B., Thant, W., Bitman, E., Liu, T., Liu, J., Paschalis, E. I., Patel, B. K., Nawrocki, C., Xu, K. H., Nieman, L. T., Ting, D. T., de Gois Macedo, B., Cheng, Y., Jiang, K., Sun, F., Thimmiah, N., Sun, S., Abelman, R. O., Bossuyt, V. I., …, & Ellisen, L. W. (2026). TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. Journal for ImmunoTherapy of Cancer, 14(4), e012265. https://doi.org/10.1136/jitc-2025-012265
Vancouver
Wu B, Thant W, Bitman E, Liu T, Liu J, Paschalis EI, et al. TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. Journal for ImmunoTherapy of Cancer. 2026;14(4):e012265. doi:10.1136/jitc-2025-012265
BibTeX
@article{Wu2026,
author = {Wu, Bogang and Thant, Win and Bitman, Elena and Liu, Ting and Liu, Jie and Paschalis, Eleftherios I and Patel, Bidish K and Nawrocki, Cole and Xu, Katherine H and Nieman, Linda T and Ting, David T and de Gois Macedo, Bruna and Cheng, Yang and Jiang, Kevin and Sun, Fengfei and Thimmiah, Nayana and Sun, Sheng and Abelman, Rachel O and Bossuyt, Veerle I and Isakoff, Steven J and Spring, Laura M and Bardia, Aditya and Ellisen, Leif W},
title = {TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {4},
pages = {e012265},
doi = {10.1136/jitc-2025-012265}
}
EUVIMED